As a matter of fact, our analysis shows that the down-regulation of BECN1 and BRCA1 expression could restore the ability of ovarian cancer cells to respond to platinum-based therapy, even in wild-type TP53 patients. Here, BECN1 is linked to ovarian carcinoma.